@FiercePharma: Teva braces for a $550M hit from Copaxone generics. Story | Follow @FiercePharma
@EricPFierce: As this story says, Merck was getting heat on Fosamax litigation it is now settling. News | Follow @EricPFierce
@CarlyHFierce: Pfizer loses Supreme Court bid to squash $142M Neurontin verdict. More | Follow @CarlyHFierce
> Merck ($MRK) says it's prepared to fork over $27.7 million to settle lawsuits with those who claim its osteoporosis drug Fosamax caused their jaw bones to deteriorate. Report
> Boehringer Ingelheim will pay a $931,000 fine for failing to preserve files related to the development and marketing of blood thinner Pradaxa. Report
> The EU has granted marketing authorization to Novo Nordisk ($NVO) for its hemophilia drug NovoEight. Report
> Eli Lilly ($LLY) has entered into India's branded generics segment with the launch of four cancer drugs. Report
> New Forest Laboratories ($FRX) CEO Brent Saunders is putting together a new team to carry out the restructuring announced last week. Release
> Lupin has received final FDA approval for its copy of ViiV Healthcare's HIV-fighting Trizivir tablets. Report
@FierceMedDev: Edwards looks to a rocky 2014 as Medtronic looms. More | Follow @FierceMedDev
@MarkHFierce: $100M gets CareFusion a minority stake in an Israeli infusion pump maker--they're old friends as well. Story | Follow @MarkHFierce
@MichaelGFierce: New Hologic CEO aims for Dx revenue growth over sale option. Item | Follow @MichaelGFierce
@GalenMoore: Genetic testing: Invitae completes a $40 million series E financing. Release | Follow @GalenMoore
> St. Jude Medical will try again another day for U.S. renal denervation study. More
> Disgraced founder, former exec team sentenced in PIP breast implant scandal. Story
Biotech News
@FierceBiotech: Alzheimers R&D: The biggest lottery in the industry, with a winning ticket worth an overnight fortune. Story | Follow @FierceBiotech
@JohnCFierce: So what are the 5 worst pharma media ops? Novartis certainly makes the list. Merck of course. Other suggestions? | Follow @JohnCFierce
@DamianFierce: The FDA's still wary of dapagliflozin, AstraZeneca and Bristol-Myers Squibb's once-rejected diabetes drug. More | Follow @DamianFierce
@EmilyMFierce: Nobel winner declares boycott of top science journals. Story via The Guardian | Follow @EmilyMFierce
> AbbVie's second PhIII hep C study confirms cocktail's promise. Item
> Danish officials cite Novo Nordisk for delay of game. Article
> Takeda sways FDA panel with its bowel disease drug despite viral risks. More
> FDA raises safety, efficacy questions for Bristol-Myers' rare-disease drug metreleptin. News
Pharma Manufacturing News
> Track-and-trace is here ... and now. Editor's corner
> FDA spanks a second Jubilant HollisterStier plant. More
> Alvogen makes a $250M biosimilars investment in Iceland. Story
> Biogen API plant gets nicked by the FDA. Article
> Hospira cuts costs by expanding drug and API production outside of the U.S. News
> Pharma Tech adds capacity as the CMO industry heats up. Report
> Feds close down importer that sold unapproved Botox and cancer drugs. Item
Biotech Research News
> Cellular Dynamics and Jain Foundation partner on stem cell models for muscular dystrophy. More
> GlaxoSmithKline initiates global cancer consortium. Item
> Report: Global malaria R&D needs $8.3B boost over next decade. Story
> Gene discovery could predict responsiveness of antidepressants. Report
> International Stem Cell Corp. finds a new way to reprogram cells. News
> 1 in 100 cancers associated with gene mutation. Article
And Finally... Some scientists in Israel are advocating for what could be the first nationwide screening campaign to test women for cancer-causing genetic mutations commonly found among Jews. Story (sub. req.)